keyword
MENU ▼
Read by QxMD icon Read
search

adjuvant treatment breast cancer

keyword
https://www.readbyqxmd.com/read/28435404/phase-ii-study-of-adjuvant-docetaxel-and-carboplatin-with-without-doxorubicin-and-cyclophosphamide-in-triple-negative-breast-cancer-a-randomised-controlled-clinical-trial
#1
Safa Najafi, Mehrdad Payandeh, Masoud Sadeghi, Vahideh Shafaei, Fateme Shojaiyan, Fereshte Abbasvandi
AIM OF THE STUDY: The aim of this trial was to compare overall survival (OS), disease-free survival (DFS), and toxicity of two adjuvant regimens in triple negative patients with Iranian ethnicity. MATERIAL AND METHODS: In a phase II trial, patients with previously untreated triple negative breaststroke cancer were randomly assigned by using docetaxel 70 mg/m(2) and carboplatin AUC = 7 every three weeks with granulocyte colony-stimulating factor for sin courses (arm A) or doxorubicin hydrochloride 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every three weeks with G-CSF for four courses followed by docetaxel 70 mg/m(2) and carboplatin AUC = 7 every three weeks with G-CSF for four courses (arm B)...
2017: Contemporary Oncology Współczesna Onkologia
https://www.readbyqxmd.com/read/28430631/loss-of-steroid-hormone-receptors-is-common-in-malignant-pleural-and-peritoneal-effusions-of-breast-cancer-patients-treated-with-endocrine-therapy
#2
Willemijne A M E Schrijver, Karianne Schuurman, Annelot van Rossum, Ton Peeters, Natalie Ter Hoeve, Wilbert Zwart, Paul J van Diest, Cathy B Moelans
Discordance in estrogen receptor alpha (ERα), progesterone receptor (PR), androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) status between primary breast cancers and solid distant metastases ("conversion") has been reported previously. Even though metastatic spread to the peritoneal and pleural cavities occurs frequently and is associated with high mortality, the rate of receptor conversion and the prognostic implications thereof remain elusive.We therefore determined receptor conversion in 91 effusion metastases (78 pleural, 13 peritoneal effusions) of 69 patients by immunohistochemistry (IHC) and in situ hybridization...
February 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/28429422/retrospective-evaluation-of-premenopausal-hormone-sensitive-breast-cancer-patients-treated-with-adjuvant-gonadotropin-releasing-hormone-analogue-anatolian-society-of-medical-oncology-asmo-study
#3
Ayşe Demirci, Necati Alkış, Faysal Dane, Ayşe Durnalı, Ömer Kamil Yazıcı, Rashad Rzayev, Serap Kaya, Doğan Yazılıtaş, Mevlüde İnanç, Melike Özçelik, Tülay Akman, Mehmet Ali Kaplan, Yusuf Günaydın, Arife Ulaş, Özlem Sönmez, Saadet Tokluoğlu, Gamze Gököz Doğu, Öznur Bal, Mahmut Gümüş
AIM: The goal of this study is to evaluate possible factors affecting the survival of patients treated with gonadotropin-releasing hormone (GnRH) analogues. METHODS: Demographic characteristics, treatment modalities, overall survival (OS) and the possible factors affecting the survival a total of 554 premenopausal breast cancer patients in Turkey evaluated retrospectively. RESULTS: The median duration of GnRH analogues use was 22 ± 13.6 (range, 1-87) months...
April 21, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28429102/improved-systemic-treatment-for-early-breast-cancer-improves-cure-rates-modifies-metastatic-pattern-and-shortens-post-metastatic-survival-35-year-results-from-the-munich-cancer-registry
#4
Dieter Hölzel, Renate Eckel, Ingo Bauerfeind, Bernd Baier, Thomas Beck, Michael Braun, Johannes Ettl, Ulrich Hamann, Marion Kiechle, Sven Mahner, Christian Schindlbeck, Johann de Waal, Nadia Harbeck, Jutta Engel
PURPOSE: Systemic therapies (ATHs) in early breast cancer have improved the survival of breast cancer (BC) patients in recent decades. The magnitude of the changes in overall, metastasis-free (MFS) and post-metastatic (PMS) survival and in the metastasis (MET) pattern will be described. PATIENT AND METHODS: We analysed 60,227 patients with a diagnosis of T-N-M0 BC between 1978 and 2013 and 11,983 patients with metastases (MET) in the Munich Cancer Registry. Patients will be divided into four time periods to identify relationships between BC and METs...
April 20, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28428927/limitations-of-personalized-medicine-and-gene-assays-for-breast-cancer
#5
David Tiberi, Laura Masucci, Daniel Shedid, Isabelle Roy, Toni Vu, Erica Patocskai, André Robidoux, Philip Wong
Adjuvant systemic treatments reduce the risk of breast cancer recurrence following the local treatment of primary stage I-III breast cancers. For patients with hormone-positive breast cancers receiving hormonal therapy, the risk of distant recurrence is under 20% and therefore, many patients may potentially be spared of chemotherapy. Consequently, several molecular signatures based on gene expression were developed to better determine which breast cancer patients would benefit from chemotherapy. We present the case of a 62-year-old woman diagnosed with an early stage hormone receptor-positive breast cancer that was treated with a partial mastectomy...
March 17, 2017: Curēus
https://www.readbyqxmd.com/read/28424560/an-exploratory-study-of-host-polymorphisms-in-genes-that-clinically-characterize-breast-cancer-tumors-and-pretreatment-cognitive-performance-in-breast-cancer-survivors
#6
Theresa A Koleck, Catherine M Bender, Beth Z Clark, Christopher M Ryan, Puja Ghotkar, Adam Brufsky, Priscilla F McAuliffe, Priya Rastogi, Susan M Sereika, Yvette P Conley
PURPOSE: Inspired by the hypothesis that heterogeneity in the biology of breast cancers at the cellular level may account for cognitive dysfunction symptom variability in survivors, the current study explored relationships between host single-nucleotide polymorphisms (SNPs) in 25 breast cancer-related candidate genes (AURKA, BAG1, BCL2, BIRC5, CCNB1, CD68, CENPA, CMC2, CTSL2, DIAPH3, ERBB2, ESR1, GRB7, GSTM1, MELK, MKI67, MMP11, MYBL2, NDC80, ORC6, PGR, RACGAP1, RFC4, RRM2, and SCUBE2), identified from clinically relevant prognostic multigene-expression profiles for breast cancer, and pretreatment cognitive performance...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28424130/invasive-pleomorphic-lobular-histology-is-an-adverse-prognostic-factor-on-survival-in-patients-with-breast-cancer
#7
Suleyman Sahin, Fatih Karatas, Gokmen U Erdem, Bekir Hacioglu, Kadri Altundag
Invasive pleomorphic lobular carcinoma (IPLC) is defined to be an uncommon and different subtype of classical invasive lobular carcinoma (ILC). This special variant is characterized by significant cytological atypia and pleomorphism which differs from the cytological uniformity of ILC. IPLC has been shown to have some poor prognostic factors such as axillary node metastasis and higher histological grade which may lead to poor clinical courses including a short relapse time, increased risk of recurrence and a decreased survival...
April 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28423398/treatment-restarting-after-discontinuation-of-adjuvant-hormone-therapy-in-breast-cancer-patients
#8
Wei He, Karin E Smedby, Fang Fang, Henrik Olsson, Sara Margolin, Per Hall, Kamila Czene
Background: Over half of breast cancer patients discontinue their adjuvant hormone therapy, permanently or temporarily. We aimed to identify predictors of treatment restarting after discontinuation of adjuvant hormone therapy and to test the hypothesis that treatment restarting is associated with better breast cancer outcomes. Methods: We conducted a population-based cohort study by linking data from the Stockholm-Gotland Breast Cancer Register, the Swedish Prescribed Drug Register, and a self-reported questionnaire...
October 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28420722/low-tumor-mitochondrial-dna-content-is-associated-with-better-outcome-in-breast-cancer-patients-receiving-anthracycline-based-chemotherapy
#9
Marjolein J A Weerts, Antoinette Hollestelle, Anieta M Sieuwerts, John A Foekens, Stefan Sleijfer, John W M Martens
In this study, we aimed to explore whether low levels of mitochondrial DNA (mtDNA) content in the primary tumor could predict better outcome for breast cancer patients receiving anthracycline-based therapies. We hypothesized that tumor cells with low mtDNA content are more susceptible to mitochondrial damage induced by anthracyclines, and thus are more susceptible to anthracycline treatment.<br /><br />Experimental Design: We measured mtDNA content by a quantitative PCR approach in 295 primary breast tumor specimens originating from two well-defined cohorts: 174 lymph node-positive patients who received adjuvant chemotherapy and 121 patients with advanced disease who received chemotherapy as first-line palliative treatment...
April 18, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28419458/therapeutic-potential-of-novel-formulated-forms-of-curcumin-in-the-treatment-of-breast-cancer-by-the-targeting-of-cellular-and-physiological-dysregulated-pathways
#10
REVIEW
Amir Tajbakhsh, Malihe Hasanzadeh, Mehdi Rezaee, Mostafa Khedri, Majid Khazaei, Soodabeh Shahid Sales, Gordon A Ferns, Seyed Mahdi Hassanian, Amir Avan
Breast cancer is among the most important causes of cancer related death in women. There is a need for novel agents for targeting key signaling pathways to either improve the efficacy of the current therapy, or reduce toxicity. There is some evidence that curcumin may have antitumor activity in breast cancer. Several clinical trials have investigated its activity in patients with breast cancer, including a recent trial in breast cancer patients receiving radiotherapy, in whom it was shown that curcumin reduced the severity of radiation dermatitis, although it is associated with low bioavailability...
April 17, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/28419141/ghrelin-is-a-prognostic-marker-and-a-potential-therapeutic-target-in-breast-cancer
#11
Malin Grönberg, Cecilia Ahlin, Ylva Naeser, Eva Tiensuu Janson, Lars Holmberg, Marie-Louise Fjällskog
Ghrelin and obestatin are gastrointestinal peptides, encoded by the same preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has been implicated in breast cancer tumorigenesis. Despite recent advances in breast cancer management the need for new prognostic markers and potential therapeutic targets in breast cancer remains high. We studied the prognostic impact of ghrelin and obestatin in women with node negative breast cancer. Within a cohort of women with breast cancer with tumor size ≤ 50 mm, no lymph node metastases and no initiation of adjuvant chemotherapy, 190 women were identified who died from breast cancer and randomly selected 190 women alive at the corresponding time as controls...
2017: PloS One
https://www.readbyqxmd.com/read/28418843/cd24-expression-and-differential-resistance-to-chemotherapy-in-triple-negative-breast-cancer
#12
Xinyu Deng, Sophia Apple, Hong Zhao, Jeongyoon Song, Minna Lee, William Luo, Xiancheng Wu, Debra Chung, Richard J Pietras, Helena R Chang
Breast cancer (BC) is a leading cause of cancer-related death in women. Adjuvant systemic chemotherapies are effective in reducing risks of recurrence and have contributed to reduced BC mortality. Although targeted adjuvant treatments determined by biomarkers for endocrine and HER2-directed therapies are largely successful, predicting clinical benefit from chemotherapy is more challenging. Drug resistance is a major reason for treatment failures. Efforts are ongoing to find biomarkers to select patients most likely to benefit from chemotherapy...
March 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28416742/model-driven-optimization-of-antiangiogenics-cytotoxics-combination-application-to-breast-cancer-mice-treated-with-bevacizumab-paclitaxel-doublet-leads-to-reduced-tumor-growth-and-fewer-metastasis
#13
Severine Mollard, Joseph Ciccolini, Diane-Charlotte Imbs, Raouf El Cheikh, Dominique Barbolosi, Sebastien Benzekry
Bevacizumab is the first-in-class antiangiogenic drug and is almost always administrated in combination with cytotoxics. Reports have shown that bevacizumab could induce a transient phase of vascular normalization, thus ensuring a better drug delivery when cytotoxics administration is adjuvant. However, determining the best sequence remains challenging. We have developed a mathematical model describing the impact of antiangiogenics on tumor vasculature. A 3.4 days gap between bevacizumab and paclitaxel was first proposed by our model...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415828/melatonin-for-the-prevention-and-treatment-of-cancer
#14
REVIEW
Ya Li, Sha Li, Yue Zhou, Xiao Meng, Jiao-Jiao Zhang, Dong-Ping Xu, Hua-Bin Li
The epidemiological studies have indicated a possible oncostatic property of melatonin on different types of tumors. Besides, experimental studies have documented that melatonin could exert growth inhibition on some human tumor cells in vitro and in animal models. The underlying mechanisms include antioxidant activity, modulation of melatonin receptors MT1 and MT2, stimulation of apoptosis, regulation of pro-survival signaling and tumor metabolism, inhibition on angiogenesis, metastasis, and induction of epigenetic alteration...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415634/a-meta-analysis-of-randomized-controlled-trials-comparing-the-efficacy-and-safety-of-anastrozole-versus-tamoxifen-for-breast-cancer
#15
Yan Yang, Wei Pan, Xinyu Tang, Shuqing Wu, Xinchen Sun
Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial. Therefore, we conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of anastrozole versus tamoxifen as adjuvant therapy in breast cancer. A systematic literature search of PubMed, Web of Science, Embase, and Cochrane library were performed to evaluate the survival benefits and toxicity profiles of patients with breast cancer who were treated with anastrozole or tamoxifen...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415013/the-effect-of-exercise-on-fatigue-and-physical-functioning-in-breast-cancer-patients-during-and-after-treatment-and-at-6-months-follow-up-a-meta-analysis
#16
REVIEW
L K Juvet, I Thune, I K Ø Elvsaas, E A Fors, S Lundgren, G Bertheussen, G Leivseth, L M Oldervoll
Breast cancer is the leading cause of cancer in women worldwide. Exercise interventions may improve physical and psychological factors during and after active breast cancer treatment. The aim of this systematic review was to assess the current knowledge regarding the efficacy of physical exercise with respect to fatigue and self-reported physical functioning. Systematic searches in Cochrane Library, Medline, Embase, Cinahl, PsycINFO, AMED and PEDro. After assessing the quality of the studies, we identified 25 randomized controlled trials that included 3418 breast cancer patients...
April 14, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28413771/management-of-aromatase-inhibitor-associated-bone-loss-aibl-in-postmenopausal-women-with-hormone-sensitive-breast-cancer-joint-position-statement-of-the-iof-cabs-ects-ieg-esceo-ims-and-siog
#17
REVIEW
Peyman Hadji, Matti S Aapro, Jean-Jacques Body, Michael Gnant, Maria Luisa Brandi, Jean Yves Reginster, M Carola Zillikens, Claus-C Glüer, Tobie de Villiers, Rod Baber, G David Roodman, Cyrus Cooper, Bente Langdahl, Santiago Palacios, John Kanis, Nasser Al-Daghri, Xavier Nogues, Erik Fink Eriksen, Andreas Kurth, Rene Rizzoli, Robert E Coleman
BACKGROUND: Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL)...
June 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28412587/accuracy-of-the-online-prognostication-tools-predict-and-adjuvant-for-early-stage-breast-cancer-patients-younger-than-50-years
#18
Ellen G Engelhardt, Alexandra J van den Broek, Sabine C Linn, Gordon C Wishart, Emiel J Th Rutgers, Anthonie O van de Velde, Vincent T H B M Smit, Adri C Voogd, Sabine Siesling, Mariël Brinkhuis, Caroline Seynaeve, Pieter J Westenend, Anne M Stiggelbout, Rob A E M Tollenaar, Flora E van Leeuwen, Laura J van 't Veer, Peter M Ravdin, Paul D P Pharaoh, Marjanka K Schmidt
IMPORTANCE: Online prognostication tools such as PREDICT and Adjuvant! are increasingly used in clinical practice by oncologists to inform patients and guide treatment decisions about adjuvant systemic therapy. However, their validity for young breast cancer patients is debated. OBJECTIVE: To assess first, the prognostic accuracy of PREDICT's and Adjuvant! 10-year all-cause mortality, and second, its breast cancer-specific mortality estimates, in a large cohort of breast cancer patients diagnosed <50 years...
April 13, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28412359/potentiation-of-docetaxel-sensitivity-by-mir-638-via-regulation-of-stard10-pathway-in-human-breast-cancer-cells
#19
Ge Zhao, Ying Li, Ting Wang
Acquired resistance to classical chemotherapeutics such as docetaxel (DTX) remains a critical challenge in breast cancer (BCa) treatment. Epigenetic modification by microRNAs (miRNAs) has been shown to play a crucial role in cancer drug resistance. Previous study, using human drug-resistant BCa tissues, has identified miR-638 as one of the most down-regulated miRNAs, but its exact roles and underlying mechanisms during the pathogenesis of chemoresistance remain to be determined. In the current study, we found that miR-638 expression was significantly down-regulated in clinical DTX-resistant BCa tissues compared to that in DTX-sensitive BCa tissues...
April 12, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28412218/evaluation-of-the-combined-use-of-metronomic-zoledronic-acid-and-coriolus-versicolor-in-intratibial-breast-cancer-mouse-model
#20
Chun-Hay Ko, Grace Gar-Lee Yue, Si Gao, Ke-Wang Luo, Wing-Sum Siu, Wai-Ting Shum, Hoi-Ting Shiu, Julia Kin-Ming Lee, Gang Li, Ping-Chung Leung, Andreas Evdokiou, Clara Bik-San Lau
ETHNOPHARMACOLOGICAL RELEVANCE: Coriolus versicolor (CV) is a mushroom traditionally used for strengthening the immune system and nowadays used as immunomodulatory adjuvant in anticancer therapy. Breast cancer usually metastasizes to the skeleton, interrupts the normal bone remodeling process and causes osteolytic bone lesions. The aims of the present study were to evaluate its herb-drug interaction with metronomic zoledronate in preventing cancer propagation, metastasis and bone destruction...
April 12, 2017: Journal of Ethnopharmacology
keyword
keyword
116441
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"